Subject Satisfaction With AbobutulinumtoxinA Treatment

Completed · Phase 4

Conditions studied: Glabellar Frown Lines

In brief

An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.

Key facts

Study ID

NCT03687736

Run by

Galderma R&D

People needed

120

Starts

2018-10-02

Expected to finish

2019-12-04

Last updated by the study team

2022-08-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Moderate to Severe Glabellar Lines at Maximum Frown
• Understands study requirements and signs an informed consent

You may not qualify if…

• Known allergy to any component of study product
• Pregnant or breast feeding or intending to get pregnant during the study
• Botulinum toxin treatment in the face within 9 months

Where it is running

• Galderma Study Site — Los Angeles, California, United States
• Galderma Study Site — San Francisco, California, United States
• Galderma Study Site — Santa Monica, California, United States
• Galderma Study Site — Greenwood Village, Colorado, United States
• Galderma Study Site — Chicago, Illinois, United States
• Galderma Study Site — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.